Trajectories of Inflammatory Markers and Post-COVID-19 Cognitive Symptoms: A Secondary Analysis of the CONTAIN COVID-19 Randomized Trial.
Jennifer A FronteraRebecca A BetenskyLiise-Anne PirofskiThomas M WisniewskiHyunah YoonMila B OrtigozaPublished in: Neurology(R) neuroimmunology & neuroinflammation (2024)
At 18 months posthospitalization for COVID-19, cognitive abnormalities were reported in 27% of patients, and below average PROMIS Global Mental and Physical Health scores occurred in 24% and 51%, respectively. However, there were no associations with measured inflammatory markers, which decreased over time.